The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting.
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability / Frassoldati, A; Guarneri, Valentina; Cagossi, K.; Bottini, A; Cavanna, L; Jovic, Gordana; Piacentini, Federico; Oliva, C; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 10s, S1 (abstract 2087):(2007), pp. s114-s114. ((Intervento presentato al convegno 30th Annual San Antonio Breast Cancer Symposium tenutosi a San Antonio, TX nel December 13-16, 2007.
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability
GUARNERI, Valentina;JOVIC, Gordana;PIACENTINI, Federico;CONTE, Pierfranco
2007-01-01
Abstract
The crosstalk between hormone- and EGFR-family pathways is considered a possible cause of hormone-resistance. To evaluate the effects of a combined blockade of these two pathways, we activated an international multicentre phase IIb double blind randomized trial in neoadjuvant setting.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
